BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 21236475)

  • 1. Tyrosine kinase A receptor (trkA): a potential marker in epithelial ovarian cancer.
    Tapia V; Gabler F; Muñoz M; Yazigi R; Paredes A; Selman A; Vega M; Romero C
    Gynecol Oncol; 2011 Apr; 121(1):13-23. PubMed ID: 21236475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer.
    Campos X; Muñoz Y; Selman A; Yazigi R; Moyano L; Weinstein-Oppenheimer C; Lara HE; Romero C
    Gynecol Oncol; 2007 Jan; 104(1):168-75. PubMed ID: 16935322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NGF/TRKA Decrease miR-145-5p Levels in Epithelial Ovarian Cancer Cells.
    Garrido MP; Torres I; Avila A; Chnaiderman J; Valenzuela-Valderrama M; Aramburo J; Oróstica L; Durán-Jara E; Lobos-Gonzalez L; Romero C
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of estradiol on the expression of angiogenic factors in epithelial ovarian cancer.
    Valladares M; Plaza-Parrochia F; Lépez M; López D; Gabler F; Gayan P; Selman A; Vega M; Romero C
    Histol Histopathol; 2017 Nov; 32(11):1187-1196. PubMed ID: 28116735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer.
    Retamales-Ortega R; Oróstica L; Vera C; Cuevas P; Hernández A; Hurtado I; Vega M; Romero C
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follicle-stimulating hormone promotes nerve growth factor and vascular endothelial growth factor expression in epithelial ovarian cells.
    Garrido MP; Bruneau N; Vega M; Selman A; Tapia JC; Romero C
    Histol Histopathol; 2020 Sep; 35(9):961-971. PubMed ID: 32369181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
    Davidson B; Reich R; Lazarovici P; Nesland JM; Skrede M; Risberg B; Tropé CG; Flørenes VA
    Clin Cancer Res; 2003 Jun; 9(6):2248-59. PubMed ID: 12796393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nerve growth factor stimulates cellular proliferation of human epithelial ovarian cancer.
    Urzua U; Tapia V; Geraldo MP; Selman A; Vega M; Romero C
    Horm Metab Res; 2012 Sep; 44(9):656-61. PubMed ID: 22411587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of nerve growth factor in poorly differentiated and advanced human esophageal cancer.
    Zhu ZW; Friess H; Wang L; Di Mola FF; Zimmermann A; Büchler MW
    Anticancer Res; 2000; 20(1A):125-32. PubMed ID: 10769644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NGF/TRKA Promotes ADAM17-Dependent Cleavage of P75 in Ovarian Cells: Elucidating a Pro-Tumoral Mechanism.
    Garrido MP; Vallejos C; Girardi S; Gabler F; Selman A; López F; Vega M; Romero C
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nerve growth factor induces the expression of chaperone protein calreticulin in human epithelial ovarian cells.
    Vera C; Tapia V; Kohan K; Gabler F; Ferreira A; Selman A; Vega M; Romero C
    Horm Metab Res; 2012 Jul; 44(8):639-43. PubMed ID: 22773372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angiogenesis.
    Vera C; Tapia V; Vega M; Romero C
    J Ovarian Res; 2014 Aug; 7():82. PubMed ID: 25296882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.
    Chanakira A; Westmark PR; Ong IM; Sheehan JP
    Gynecol Oncol; 2017 Apr; 145(1):167-175. PubMed ID: 28148395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
    Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenomedullin promotes angiogenesis in epithelial ovarian cancer through upregulating hypoxia-inducible factor-1α and vascular endothelial growth factor.
    Zhang Y; Xu Y; Ma J; Pang X; Dong M
    Sci Rep; 2017 Jan; 7():40524. PubMed ID: 28091613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nerve growth factor induces vascular endothelial growth factor expression in granulosa cells via a trkA receptor/mitogen-activated protein kinase-extracellularly regulated kinase 2-dependent pathway.
    Julio-Pieper M; Lozada P; Tapia V; Vega M; Miranda C; Vantman D; Ojeda SR; Romero C
    J Clin Endocrinol Metab; 2009 Aug; 94(8):3065-71. PubMed ID: 19454577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased expression of protein kinase CK2α correlates with poor patient prognosis in epithelial ovarian cancer.
    Ma Z; Wang X; He J; Xia J; Li Y
    PLoS One; 2017; 12(3):e0174037. PubMed ID: 28355289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.
    Komatsu H; Oishi T; Itamochi H; Shimada M; Sato S; Chikumi J; Sato S; Nonaka M; Sawada M; Wakahara M; Umekita Y; Harada T
    Int J Gynecol Cancer; 2017 Sep; 27(7):1325-1332. PubMed ID: 28557832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.